EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 35 / Numéro 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 1189-1193 Références
Open Access
Numéro
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1189 - 1193
Section Les anticorps à l’aune des analyses médico-économiques
DOI https://doi.org/10.1051/medsci/2019212
Publié en ligne 6 janvier 2020
  1. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012 ; 380: 1819–1828. [CrossRef] [PubMed] [Google Scholar]
  2. Editorial. Alemtuzumab for multiple sclerosis. Lancet 2012; 380: 1792. [Google Scholar]
  3. Montgomery SM, Kusel J, Nicholas R, et al. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. J Med Econ. 2017 ; 20: 962–973. [CrossRef] [PubMed] [Google Scholar]
  4. Piena MA, Heisen M, Wormhoudt LW, et al. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. J Med Econ. 2018 ; 21: 968–976. [CrossRef] [PubMed] [Google Scholar]
  5. Stanisic S, Bertolotto A, Berto P, et al. The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. GRHTA. 2019 ; 21: S338. [Google Scholar]
  6. Marmor MF, Martin LJ, Tharpe S, et al. Osmotically induced retinal detachment in the rabbit and primate. Electron miscoscopy of the pigment epithelium. Invest Ophthalmol Vis Sci 1980 ; 19: 1016–1029. [PubMed] [Google Scholar]
  7. de Oliveira Dias JR, Badaró E, Novais EA, et al. Preclinical investigations of intravitreal ziv-aflibercept. Ophthalmic Surg Lasers Imaging Retina 2014 ; 45: 577–584. [CrossRef] [PubMed] [Google Scholar]
  8. Mansour AM, Ashraf M, Charbaji A, et al. Two-year outcomes of intravitreal ziv-aflibercept. Br J Ophthalmol 2018 ; 102: 1387–1390. [CrossRef] [PubMed] [Google Scholar]
  9. Mansour AM, Chhablani J, Antonios RS, et al. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration. Br J Ophthalmol 2016 ; 100: 1629–1633. [CrossRef] [PubMed] [Google Scholar]
  10. Chan EW, Eldeeb M, Govindhari V, et al. Treatment outcomes of ziv-aflibercept for treatment-naïve polypoidal choroidal vasculopathy. Acta Ophthalmol 2018 ; 96: e258–e259. [CrossRef] [PubMed] [Google Scholar]
  11. Chhablani J, Dedhia CJ, Peguda HK, et al. Short-term safety of 2 mg intravitreal ziv-aflibercept. Retina 2017 ; 37: 1859–1865. [CrossRef] [PubMed] [Google Scholar]
  12. Mansour AM, Al-Ghadban SI, Yunis MH, et al. Ziv-aflibercept in macular disease. Br J Ophthalmol 2015 ; 99: 1055–1059. [CrossRef] [PubMed] [Google Scholar]
  13. Andrade GC, Dias JR, Maia A, et al. Intravitreal injections of ziv-aflibercept for diabetic macular edema: a pilot study. Retina 2016 ; 36: 1640–1645. [CrossRef] [PubMed] [Google Scholar]
  14. Singh SR, Dogra A, Stewart M. Intravitreal ziv-aflibercept: clinical effects and economic impact. Asia Pac J Ophthalmol (Phila) 2017 ; 6: 561–568. [Google Scholar]
  15. Magdelaine-Beuzelin C, Pinault C, Paintaud G, et al. Therapeutic antibodies in ophthalmology: old is new again. MAbs 2010 ; 2: 176–180. [CrossRef] [PubMed] [Google Scholar]
  16. CATT Research Group, Martin DF, Maguire MG, Ranibizumab and Bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011 ; 364: 1897–1908. [Google Scholar]
  17. Chakravarthy U, Harding SP, Rogers CA, et al. IVAN 2-years Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013 ; 2012: 382 1258–1267. [Google Scholar]
  18. Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013 ; 97: 266–271. [CrossRef] [PubMed] [Google Scholar]
  19. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus Bevacizumab for neovascular age-related macular degeneration: results from the GEFAL non-inferiority randomized trial. Ophtalmol 2013 ; 120: 2300–2309. [CrossRef] [Google Scholar]
  20. Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015 ; 122: 146–152. [Google Scholar]
  21. Schauwvlieghe AM, Dijkman G, Hooymans JM, et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD study. PLoS One 2016 ; 11: e0153052. [CrossRef] [Google Scholar]
  22. Chast F.. Coût du traitement de la DMLA: au cœur de la polémique. Rev Prat (médecine générale) 2017 ; 975: 121–122. [Google Scholar]
  23. Rapport annuel de la cour des comptes. Paris, 2018: p. 268. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.